ARCHIVES

Over Half of ALK-Positive NSCLC Patients Responded To Crizotinib In Colorado Study

This article is from The Cancer Letter archive.

Vol. 33 No. 11 | November 26, 2010

Download PDF Visit The Full Archive

Related Articles

Cancer Groups In Campaign To Draft Pazdur For FDA.

March 2, 2001

Bypass Budget Going to White House Next Month Will Seek Optimal Funding for Cancer Program

August 22, 1980

In Brief: Koprowski, Niederhuber, Engstrom Chair DCE, DCT, DCPC BSCs; Roentgen Ray Officers Named

June 19, 1987

DO RFAs cut Into R01 Grant Pool? Board Asks

July 2, 1999

Adherez Issued U.S. Patent for Catenin Molecule Inhibition.

July 4, 2003

Compendium Drops Listing of Aranesp for Anemia of Cancer.

February 23, 2007